Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America
June 14 2017 - 9:00AM
Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the
"Company"), announces its new managed access program partnership
with myTomorrows at the European League Against Rheumatism (EULAR)
Congress in Madrid, Spain between June 14 and 17. Cytori and
myTomorrows share the goal of providing early and ethical access to
Cytori’s Habeo Cell Therapy™ to patients in Europe, Middle East and
Latin America.
“Providing compliant access to patients who may benefit from
therapies in clinical development is the objective of Managed
Access Programs (MAP). Habeo Cell Therapy fits the defined
parameters of a MAP-eligible therapy. Towards that end, Cytori is
excited to leverage myTomorrow’s expertise and expanded scope to
take our MAP in a new direction,” said John Harris, Vice President
and General Manager at Cytori. “We look forward to kicking
off our relationship at the EULAR congress in Madrid, Spain this
week.”
myTomorrows is an innovative and fully integrated organization
dedicated to providing fully compliant early access to innovative
therapeutics in advance of the products full marketing
authorization in the countries that it serves. myTomorrows will
serve as Cytori’s exclusive MAP for patients with
scleroderma-associated hand dysfunction. myTomorrows will leverage
its footprint to provide patients early access to Habeo Cell
Therapy for the Middle East and Latin America in addition to
Europe.
“The opportunity to collaborate with Cytori to lend support to
patients in need is exactly in line with our team’s mission and
core competences,” said Govert Schouten, Co-Founder and Chief
Business Officer at myTomorrows.
The EULAR Congress is considered to be a major event in the
global rheumatology network and seeks to serve as a platform to
facilitate interactions between patients, medical doctors,
scientists, health professionals and industry surrounding
scientific and clinical information. Cytori Therapeutics’
booth is #47 in the main congress hall, where we will highlight the
STAR and SCLERADEC-II clinical trials that are currently in
progress in the U.S. and France, respectively.
Representatives will be available to answer questions about the
Habeo Cell Therapy Managed Access Program.
myTomorrows will be responsible for the design, implementation,
and performance of the Managed Access Program and their
Netherlands-headquartered and field-based teams will apply their
knowledge and expertise toward physician and patient support, legal
and regulatory administration, pharmacovigilance, logistics, and
data collection.
About Cytori Therapeutics
Cytori is a therapeutics company developing regenerative and
oncologic therapies from its proprietary cell therapy and
nanoparticle platforms for a variety of medical conditions.
Data from preclinical studies and clinical trials suggest
that Cytori Cell Therapy™ acts principally by improving blood flow,
modulating the immune system, and facilitating wound repair.
As a result, Cytori Cell Therapy™ may provide benefits across
multiple disease states and can be made available to the physician
and patient at the point-of-care through Cytori’s proprietary
technologies and products. Cytori Nanomedicine™ is developing
liposome encapsulated therapies for regenerative medicine and
oncologic indications. For more information, please visit
www.cytori.com.
About myTomorrows
myTomorrows provides information about treatment options and
facilitates access to pre-approval medicines for physicians and
their patients with unmet medical needs. myTomorrows
supports these activities via its data-infused digital marketplace
that combines actionable and uniform public information about Early
Access Programs and Clinical Trials. To learn more, please visit:
www.mytomorrows.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release includes forward-looking statements regarding
events, trends and business prospects, which may affect our future
operating results and financial position. Such statements,
including, but not limited to, statements regarding availability
and implementation of the Habeo Cell Therapy Managed Access
Program are subject to risks and uncertainties that could
cause our actual results and financial position to differ
materially. Some of these risks and uncertainties include: risks in
development, manufacture and commercial launch of Cytori’s Habeo
Cell Therapy product; risks in the conduct of clinical trials,
including STAR and SCLERADEC-II; risks associated with potential
benefits of Cytori’s Habeo Cell Therapy product; risks in the
collection and results of clinical data; risks associated with
development of Cytori’s clinical pipeline; final clinical outcomes;
regulatory risks and uncertainties; risks related to dependence on
third party performance; and other risks and uncertainties
described under the "Risk Factors" section in Cytori's Securities
and Exchange Commission Filings on Form 10-K and Form 10-Q.
Cytori assumes no responsibility to update or revise any
forward-looking statements contained in this press release to
reflect events, trends or circumstances after the date of this
communication.
Cytori Therapeutics, Inc.
Tiago Girao, 1-858-458-0900
ir@cytori.com
Source: Cytori Therapeutics
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Sep 2023 to Sep 2024